Upcoming trial readouts

Name: Bio Catalyst Calendar — source-anchored biotech/pharma catalyst dates
Creator: Bio Catalyst Calendar
License: https://www.usa.gov/government-works

600 upcoming events · verified as of 2026-09-20 · soonest first.

All · Readouts · AdComm · Recent approvals

Date	Event	Company	Drug	Official source & verification
2026-09-21 in 1d ESTIMATED	READOUT CardiolRx in Recurrent Pericarditis (MAVERIC Phase-3) Phase 3 · Recurrent Pericarditis	CRDL Cardiol Therapeutics Inc.	CardiolRx	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-09-22 in 2d ESTIMATED	READOUT A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and i Phase 1/2 · Solid Tumor, Melanoma	ImmVira Pharma Co. Ltd	T3011, T3011 + pembrolizumab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-09-22 in 2d ESTIMATED	READOUT A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Mono Phase 2 · Waldenstrom Macroglobulinemia, Waldenstrom's Macroglobulinemia Recurrent	ONC BeOne Medicines Ltd.	Sonrotoclax, Zanubrutinib	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-09-22 in 2d ESTIMATED	READOUT Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1403 an Phase 1/2 · Norovirus Acute Gastroenteritis	ModernaTX, Inc.	mRNA-1403, mRNA-1405	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-09-23 in 3d ESTIMATED	READOUT Study to Test the Safety and Tolerability of PF-07220060 in Participants With Ad Phase 2 · Liposarcoma, Prostate Cancer	PFE PFIZER INC	PF-07220060, Letrozole, Fulvestrant, Mid	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-09-24 in 4d ESTIMATED	READOUT An Open-label, Study to Assess Safety, Efficacy and Cellular Kinetics of YTB323 Phase 1/2 · Systemic Lupus Erythematosus, Lupus Nephritis	NVS NOVARTIS AG	YTB323	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-09-27 in 7d ESTIMATED	READOUT A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whethe Phase 3 · Lupus Erythematosus, Systemic	BIIB BIOGEN INC.	Litifilimab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-09-28 in 8d ESTIMATED	READOUT A Study to Evaluate INCB099280 in Participants With Advanced Cutaneous Squamous Phase 2 · Cutaneous Squamous Cell Carcinoma	INCY INCYTE CORP	INCB099280	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-09-28 in 8d ESTIMATED	READOUT A Study of AT-02 in Subjects With Systemic Amyloidosis. Phase 2 · Amyloidosis; Systemic	Attralus, Inc.	AT02	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-09-28 in 8d ESTIMATED	READOUT A Phase 2/3 Trial to Assess the Efficacy and Safety of OCU410ST for Stargardt Di Phase 2/3 · Stargardt Disease	OCGN Ocugen, Inc.	OCU410ST	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-09-28 in 8d ESTIMATED	READOUT An Open-label, Single-arm Study to Evaluate Pharmacokinetics and Safety of Subcu Phase 3 · Hidradenitis Suppurativa	MLTX MoonLake Immunotherapeutics	Sonelokimab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-09-29 in 9d ESTIMATED	READOUT Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Rela Phase 3 · Eosinophilic Granulomatosis With Polyangiitis	GlaxoSmithKline	Depemokimab, Mepolizumab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-09-29 in 9d ESTIMATED	READOUT Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Pa Phase 2 · Asthma	SNY Sanofi	Amlitelimab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-09-30 in 10d ESTIMATED	READOUT An Adaptive Phase II/III, Two-Part, Double-Blind, Randomized, Placebo-controlled Phase 2/3 · Refractory Schizophrenia	SyneuRx International (Taiwan) Cor	NaBen®	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-09-30 in 10d ESTIMATED	READOUT A Study of BI-1206 in Combination With Rituximab With or Without Acalabrutinib i Phase 1/2 · Indolent B-Cell Non-Hodgkin Lymphoma	BioInvent International AB	BI-1206, Rituximab, Acalabrutinib	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-09-30 in 10d ESTIMATED	READOUT A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, RO Phase 1/2 · Locally Advanced Solid Tumors, Metastatic Solid Tumors	TPB Turning Point Brands, Inc.	Oral repotrectinib (TPX-0005)	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-09-30 in 10d ESTIMATED	READOUT Linerixibat Long-term Safety, and Tolerability Study Phase 3 · Cholestasis	GlaxoSmithKline	Linerixibat	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-09-30 in 10d ESTIMATED	READOUT A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Part Phase 3 · Carcinoma, Non-Small-Cell Lung	Hoffmann-La Roche	Entrectinib, Crizotinib	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-09-30 in 10d ESTIMATED	READOUT A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whethe Phase 3 · Lupus Erythematosus, Systemic	BIIB BIOGEN INC.	Litifilimab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-09-30 in 10d ESTIMATED	READOUT A Study to Test the Efficacy and Safety of Staccato Alprazolam in Study Particip Phase 3 · Stereotypical Prolonged Seizures	UCB Biopharma SRL	Staccato alprazolam	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-09-30 in 10d ESTIMATED	READOUT A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizum Phase 3 · Gastric Neoplasms, Gastroesophageal Adenocarcinoma	JAZZ Jazz Pharmaceuticals plc	Zanidatamab, Tislelizumab, Trastuzumab,	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-09-30 in 10d ESTIMATED	READOUT A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab Phase 3 · Non-Small Cell Lung Cancer	AZN ASTRAZENECA PLC	Durvalumab, Oleclumab, Monalizumab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-09-30 in 10d ESTIMATED	READOUT Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Phase 1/2 · KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small Cell Lung	NVS NOVARTIS AG	JDQ443, trametinib, Ribociclib, cetuxima	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-09-30 in 10d ESTIMATED	READOUT A Phase 1/2 Study to Evaluate the Safety, Tolerability and PK of JIN-A02 in Pati Phase 1/2 · EGFR Mutant Advanced Non-small Cell Lung Cancer	J Ints Bio	JIN-A02	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-09-30 in 10d ESTIMATED	READOUT Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G Phase 2 · Advanced NSCLC, Metastatic Lung Cancer	Mirati Therapeutics Inc.	Adagrasib oral dose of 400 mg twice dail	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-09-30 in 10d ESTIMATED	READOUT A Trial of Lu AG13909 in Participants With Congenital Adrenal Hyperplasia Phase 1/2 · Congenital Adrenal Hyperplasia	H. Lundbeck A/S	Lu AG13909	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-09-30 in 10d ESTIMATED	READOUT A Study to Assess the Efficacy and Safety of Daily OM-85 in Young Children With Phase 2 · Recurrent Wheezing, Wheezing Lower Respiratory Illness	OM Pharma SA	OM-85	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-09-30 in 10d ESTIMATED	READOUT A Study to Evaluate INCB099280 in Participants With Select Solid Tumors Who Are Phase 2 · Advanced Solid Tumor	INCY INCYTE CORP	INCB099280	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-09-30 in 10d ESTIMATED	READOUT A Study of BMS-986449 With and Without Nivolumab in Participants With Advanced S Phase 1/2 · Advanced Solid Tumors	BMY BRISTOL MYERS SQUIBB CO	BMS-986449, Nivolumab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-09-30 in 10d ESTIMATED	READOUT Azeliragon in MGMT Unmethylated Glioblastoma Phase 2 · Glioblastoma	Cantex Pharmaceuticals	Azeliragon	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-09-30 in 10d ESTIMATED	READOUT Safety, Tolerability, and Exploratory Efficacy Study of Intrathecally Administer Phase 1/2 · Amyotrophic Lateral Sclerosis	UniQure Biopharma B.V.	AMT-162	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-09-30 in 10d ESTIMATED	READOUT To Assess the Safety and Efficacy of SP-002 with Vismodegib for the Treatment of Phase 2 · Basal Cell Carcinoma	Stamford Pharmaceuticals, Inc.	SP-002, Vismodegib	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-09-30 in 10d ESTIMATED	READOUT A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as Phase 1/2 · Extensive Stage-small Cell Lung Cancer	Daiichi Sankyo	Ifinatamab deruxtecan, Atezolizumab, Car	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-09-30 in 10d ESTIMATED	READOUT A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osime Phase 3 · Metastatic Non-small Cell Lung Cancer	AZN ASTRAZENECA PLC	Dato-DXd, Osimertinib, Pemetrexed, Carbo	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-09-30 in 10d ESTIMATED	READOUT A Study to Evaluate Solrikitug in Participants With COPD (ZION) Phase 2 · COPD	Uniquity One (UNI)	Biological: Solrikitug low dose, Biologi	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-09-30 in 10d ESTIMATED	READOUT ARTEMIS-008：HS-20093 Compared With Topotecan in Subjects With Relapsed Small Cel Phase 3 · Small Cell Lung Cancer	Hansoh BioMedical R&D Company	HS-20093, Topotecan	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-09-30 in 10d ESTIMATED	READOUT An Extension and Crossover Vaccination Study on the Immune Response and Safety o Phase 3 · Respiratory Syncytial Virus Infections	GlaxoSmithKline	RSVPreF3 OA vaccine	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-09-30 in 10d ESTIMATED	READOUT A Study to Evaluate the Efficacy and Safety of 2 Doses of EYE103 Compared With R Phase 2/3 · Diabetic Macular Edema (DME)	EyeBiotech Ltd.	Ranibizumab, EYE103	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-09-30 in 10d ESTIMATED	READOUT A Clinical Study to Investigate the Effect of Oral Neflamapimod on Motor Recover Phase 2 · Moderate to Severe Acute Ischaemic Stroke, Ischaemic Stroke	EIP Pharma Inc	Neflamapimod	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-09-30 in 10d ESTIMATED	READOUT A Study to Investigate the Long-term Safety, Tolerability and Efficacy of Balina Phase 2 · Colitis Ulcerative, Crohn's Disease	SNY Sanofi	balinatunfib, balinatunfib-matching plac	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-09-30 in 10d ESTIMATED	READOUT Study of ARO-DIMERPA in Adult Participants With Mixed Hyperlipidemia Phase 1/2 · Hyperlipidemia; Mixed	ARWR ARROWHEAD PHARMACEUTICALS, I	ARO-DIMERPA	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-09-30 in 10d ESTIMATED	READOUT A Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruqu Phase 2 · Colorectal Cancer	Kahr Bio Australia Pty Ltd	DSP107 + Atezolizumab, Fruquintinib	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-09-30 in 10d ESTIMATED	READOUT Clinical Study to Collect and Analyze Dental Plaque and Oral Health Measures in Phase 4 · Gingivitis, Plaque	CL COLGATE PALMOLIVE CO	sodium monofluorophosphate toothpaste	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10 (month) in 11d ESTIMATED	READOUT A Safety, Tolerability and Efficacy Study of Sernova's Cell Pouch™ for Clinical Phase 1/2 · Type 1 Diabetes Mellitus	Sernova Biotherapeutics Inc.	Sernova Cell Pouch	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10 (month) in 11d ESTIMATED	READOUT A Study of Baricitinib (LY3009104) in Participants From 1 Year to Less Than 18 Y Phase 3 · Systemic Juvenile Idiopathic Arthritis	LLY ELI LILLY & Co	Baricitinib, Tocilizumab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10 (month) in 11d ESTIMATED	READOUT Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Check Phase 1/2 · Select Advanced Solid Tumors	IMCR Immunocore Holdings plc	Brenetafusp, Brenetafusp and pembrolizum	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10 (month) in 11d ESTIMATED	READOUT Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients Phase 2 · Melanoma, Head and Neck Squamous Cell Carcinoma	Vyriad, Inc.	VV1, Cemiplimab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10 (month) in 11d ESTIMATED	READOUT Study of LAM561 Acid in Pediatric Patients With Malignant Glioma and Other Advan Phase 1/2 · High-grade Glioma, Solid Tumor, Unspecified, Child	Laminar Pharmaceuticals	LAM561	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-01 in 11d ESTIMATED	READOUT A Phase 3 Study to Evaluate the Safety and Efficacy of Efgartigimod PH20 Subcuta Phase 3 · Primary Immune Thrombocytopenia	ARGX ARGENX SE	efgartigimod PH20 SC	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10 (month) in 11d ESTIMATED	READOUT A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus V Phase 3 · Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma	Loxo Oncology, Inc.	Pirtobrutinib, Venetoclax, Rituximab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10 (month) in 11d ESTIMATED	READOUT RAdiolabeled Perfusion to Identify Coronary Artery Disease Using WAter To Evalua Phase 3 · Coronary Artery Disease	MedTrace Pharma A/S	[O-15]-Water PET Myocardial Perfusion Im	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10 (month) in 11d ESTIMATED	READOUT Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects Phase 3 · Plaque Psoriasis	Organon and Co	tapinarof cream, 1%	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-01 in 11d ESTIMATED	READOUT A Masked, Placebo-controlled Study to Assess Iptacopan in Age-related Macular De Phase 2 · Age-Related Macular Degeneration	NVS NOVARTIS AG	Iptacopan (LNP023)	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10 (month) in 11d ESTIMATED	READOUT Dazucorilant in Patients With Amyotrophic Lateral Sclerosis Phase 2 · Amyotrophic Lateral Sclerosis	CORT CORCEPT THERAPEUTICS INC	Dazucorilant 300 mg, Dazucorilant 150 mg	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10 (month) in 11d ESTIMATED	READOUT Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD Phase 3 · AMD, nAMD	ABBV AbbVie Inc.	ABBV-RGX-314 Dose 1, ABBV-RGX-314 Dose 2	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-01 in 11d ESTIMATED	READOUT SPEARHEAD-3 Pediatric Study Phase 1/2 · Synovial Sarcoma, Malignant Peripheral Nerve Sheath Tumor (MPNST)	USWM CT, LLC	Afamitresgene autoleucel	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10 (month) in 11d ESTIMATED	READOUT A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3) Phase 3 · Focal Onset Seizures	XENE Xenon Pharmaceuticals Inc.	XEN1101	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10 (month) in 11d ESTIMATED	READOUT A Study of GEn-1124 in Subjects With Acute Respiratory Distress Syndrome (ARDS) Phase 2 · Respiratory Distress Syndrome, Acute	GEn1E Lifesciences	GEn-1124	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10 (month) in 11d ESTIMATED	READOUT A Study to Evaluate the Safety and PK of CRN04894 for the Treatment of Cushing's Phase 1/2 · Cushing Syndrome, Cushing Disease	Crinetics Pharmaceuticals Inc.	atumelnant	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10 (month) in 11d ESTIMATED	READOUT A Study Evaluating the Safety and Efficacy of PRV111, PRV211, and PRV131 in Subj Phase 2/3 · Oral Squamous Cell Carcinoma	Privo Technologies	PRV211 (Intraoperative Cisplatin System)	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-01 in 11d ESTIMATED	READOUT Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Phase 2 · Locally Advanced Unresectable or Metastatic Solid Tumors Including Esophageal Cancer, Esophageal Adenocarcinoma	Taiho Oncology, Inc.	Futibatinib, Pembrolizumab, Cisplatin, 5	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10 (month) in 11d ESTIMATED	READOUT A Study YL201 in Patients With Selected Advanced Solid Tumors Phase 1/2 · Advanced Solid Tumor	MediLink Therapeutics (Suzhou) Co.	YL201 for Injection	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10 (month) in 11d ESTIMATED	READOUT Effect of 10 mg Xanamem on Dementia Due to Alzheimer's Disease Phase 2/3 · Dementia Moderate, Dementia, Mild	Actinogen Medical	Xanamem	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10 (month) in 11d ESTIMATED	READOUT A Study to Assess the Efficacy, Safety, and Pharmacokinetics of Debio 4326 in Pe Phase 3 · Central Precocious Puberty	Debiopharm International SA	Debio 4326	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-01 in 11d ESTIMATED	READOUT A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Part Phase 3 · Heart Failure, Systemic Inflammation	NVO NOVO NORDISK A S	Ziltivekimab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10 (month) in 11d ESTIMATED	READOUT Effect of Retatrutide Compared With Placebo in Participants With Type 2 Diabetes Phase 3 · Type 2 Diabetes	LLY ELI LILLY & Co	Retatrutide	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10 (month) in 11d ESTIMATED	READOUT Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory F Phase 2/3 · Focal Epilepsy	BHVN Biohaven Ltd.	BHV-7000, BHV-7000	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10 (month) in 11d ESTIMATED	READOUT A Study to Evaluate Efficacy and Safety of Intravenous Sabirnetug in Participant Phase 2 · Alzheimer Disease	ABOS Acumen Pharmaceuticals, Inc.	sabirnetug	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10 (month) in 11d ESTIMATED	READOUT A Phase 2 Trial of ENV-101 in Patients With Lung Fibrosis (WHISTLE-PF Trial) Phase 2 · Idiopathic Pulmonary Fibrosis, Progressive Fibrosing Interstitial Lung Disease	Endeavor Biomedicines, Inc.	ENV-101	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10 (month) in 11d ESTIMATED	READOUT A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urtica Phase 3 · Chronic Spontaneous Urticaria	CLDX Celldex Therapeutics, Inc.	barzolvolimab, Matching placebo	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10 (month) in 11d ESTIMATED	READOUT A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urtica Phase 3 · Chronic Spontaneous Urticaria	CLDX Celldex Therapeutics, Inc.	barzolvolimab, Matching placebo	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10 (month) in 11d ESTIMATED	READOUT ADAPT Study: Long-term Safety Study of INZ-701 in Patients With ENPP1 Deficiency Phase 2 · Gene Mutations, Pseudoxanthoma Elasticum	Inozyme Pharma	INZ-701	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10 (month) in 11d ESTIMATED	READOUT Evaluation of Maralixibat in Pruritus Associated With General Cholestatic Liver Phase 3 · Cholestatic Liver Disease (Except ALGS, PFIC, PBC and PSC)	MIRM Mirum Pharmaceuticals, Inc.	Maralixibat	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10 (month) in 11d ESTIMATED	READOUT A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration Phase 3 · Wet Age Related Macular Degeneration, wAMD	EYPT EyePoint, Inc.	EYP-1901, Aflibercept (2.0 mg)	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10 (month) in 11d ESTIMATED	READOUT A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Prel Phase 1/2 · Alopecia Areata (AA)	Aldena Therapeutics	ALD-102 Solution	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10 (month) in 11d ESTIMATED	READOUT A Study in Adult Participants With EoE to Evaluate Vonoprazan 20 mg Compared to Phase 2 · Eosinophilic Esophagitis	PHAT Phathom Pharmaceuticals, Inc	Vonoprazan	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10 (month) in 11d ESTIMATED	READOUT A Study to Assess the Safety, Tolerability, and Efficacy of IMVT-1402 in Partici Phase 2 · Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus	Immunovant Sciences GmbH	IMVT-1402	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10 (month) in 11d ESTIMATED	READOUT Evaluation of Efficacy and Safety of Iloperidone for the Treatment of Participan Phase 2 · Hypertension, Uncontrolled Hypertension	VNDA Vanda Pharmaceuticals Inc.	iloperidone	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10 (month) in 11d ESTIMATED	READOUT A Study to Assess Anktiva in Patients With Long Covid-19. Phase 2 · Long COVID	IBRX ImmunityBio, Inc.	N-803 (IL-15 Superagonist)	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10 (month) in 11d ESTIMATED	READOUT A Study to Assess How Effective and Safe NVD003 is for Treating Patients With Co Phase 3 · Congenital Pseudarthrosis of Tibia	Novadip Biosciences	NVD003, Iliac Crest Bone Graft	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10 (month) in 11d ESTIMATED	READOUT A Study Evaluating TRIV-509 in Atopic Dermatitis Phase 2 · Atopic Dermatitis	Triveni Bio	TRIV-509	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10 (month) in 11d ESTIMATED	READOUT A Study to Evaluate KYN-5356 in Adults With Cognitive Impairment Associated With Phase 2 · Cognitive Impairment Associated With Schizophrenia (CIAS)	Kynexis B.V.	KYN-5356 low dose, KYN-5356 Medium Dose,	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-01 in 11d ESTIMATED	READOUT A Study to Evaluate the Efficacy, Safety and Pharmacokinetics of CDI-988 in Heal Phase 1/2 · Norovirus	COCP Cocrystal Pharma, Inc.	CDI-988, Snow Mountain Virus	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10 (month) in 11d ESTIMATED	READOUT A Study of NT 201 in Adults With Moderate to Severe Platysma Prominence in Europ Phase 3 · Neuromuscular Agents, Peripheral Nervous System Agents	Merz Aesthetics GmbH	NT 201, NT 201 Placebo	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10 (month) in 11d ESTIMATED	READOUT Tacrolimus Ophthalmic Solution for the Treatment of Non-infectious Anterior Uvei Phase 2 · Non-infectious Anterior Uveitis	Novaliq GmbH	Tacrolimus ophthalmic solution	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10 (month) in 11d ESTIMATED	READOUT Single-site Pilot Study Evaluating the Effect of QLS-111 Ophthalmic Solution on Phase 2 · Non-proliferative Diabetic Retinopathy (NPDR), Open-angle Glaucoma (OAG)	Qlaris Bio, Inc.	QLS-111 Ophthalmic Solution (0.015%), QL	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10 (month) in 11d ESTIMATED	READOUT Study of DISC-0974-201 in Participants With IBD and Anemia Phase 2 · Inflammatory Bowel Disease (IBD), Anemia	IRON Disc Medicine, Inc.	DISC-0974	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10 (month) in 11d ESTIMATED	READOUT HP-211 Safety and Proof of Concept Dose Ranging Study in Patients With Type 2 Di Phase 2 · Type 2 Diabetes	Housey Healthcare ULC	HP-211	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10 (month) in 11d ESTIMATED	READOUT Randomized Single Center Study to Evaluate Tolerability, Symptoms, and Visual Fu Phase 4 · Dry Eye Disease (DED)	Andover Research Eye Institute	Preservative Free Polyethylene glycol 40	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10 (month) in 11d ESTIMATED	READOUT A Study to Assess the Safety and Efficacy of AGN-151586 Injections for the Treat Phase 2 · Forehead Lines	ABBV AbbVie Inc.	AGN-151586	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-02 in 12d ESTIMATED	READOUT Long-term Follow-up Study of Risdiplam in Participants With Spinal Muscular Atro Phase 4 · Spinal Muscular Atrophy	Genentech, Inc.	Risdiplam	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-02 in 12d ESTIMATED	READOUT Multiple Dose Intraventricular Administration of Rhenium-186 NanoLiposome for Le Phase 1/2 · Leptomeningeal Metastasis	CNSY CERENOME, INC.	186RNL	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-02 in 12d ESTIMATED	READOUT A Trial of TAK-861 for the Treatment of Narcolepsy With Cataplexy Phase 3 · Narcolepsy Type 1 (NT1), Narcolepsy With Cataplexy	TAK TAKEDA PHARMACEUTICAL CO LTD	TAK-861	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-05 in 15d ESTIMATED	READOUT A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polyc Phase 3 · Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis	Swedish Orphan Biovitrum	Pacritinib, Physician's Choice medicatio	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-05 in 15d ESTIMATED	READOUT A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1189, in 10- to 3 Phase 1/2 · Epstein-Barr Virus Infection	ModernaTX, Inc.	mRNA-1189	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-05 in 15d ESTIMATED	READOUT A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis As Phase 3 · Psychosis Associated With Alzheimer's Disease	Karuna Therapeutics, Inc., a Brist	KarXT	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-05 in 15d ESTIMATED	READOUT A Study of Rozanolixizumab in Pediatric Study Participants With Moderate to Seve Phase 2/3 · Generalized Myasthenia Gravis	UCB Biopharma SRL	rozanolixizumab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-06 in 16d ESTIMATED	READOUT A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Part Phase 3 · Idiopathic Pulmonary Fibrosis	BMY BRISTOL MYERS SQUIBB CO	BMS-986278, BMS-986278 Placebo	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-07 in 17d ESTIMATED	READOUT Study to Assess the Long-term Safety of Dupilumab Administered in Participants ≥ Phase 3 · Atopic Dermatitis	REGN REGENERON PHARMACEUTICALS, I	Dupilumab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-07 in 17d ESTIMATED	READOUT A Study to Characterize the Safety and Immunogenicity of AZD6489 in Participants Phase 1/2 · RSV Respiratory Syncytial Virus	AZN ASTRAZENECA PLC	AZD6489, Licensed RSV vaccine #1, Licens	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-08 in 18d ESTIMATED	READOUT A Study of Immune Checkpoint Inhibitor Combinations With Axitinib in Participant Phase 2 · Renal Cell Carcinoma	Hoffmann-La Roche	Tobemstomig, Tiragolumab, Pembrolizumab,	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-09 in 19d ESTIMATED	READOUT Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants W Phase 3 · Hidradenitis Suppurativa	INCY INCYTE CORP	Ruxolitinib Cream, Vehicle Cream	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-09 in 19d ESTIMATED	READOUT Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants W Phase 3 · Hidradenitis Suppurativa	INCY INCYTE CORP	Ruxolitinib Cream, Vehicle Cream	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-10 in 20d ESTIMATED	READOUT Study to Evaluate HDM1002 Tablets in Adults With Type 2 Diabetes Mellitus Phase 3 · Type 2 Diabetes	Hangzhou Zhongmei Huadong Pharmace	HDM1002 200 mg, HDM1002 400 mg	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-12 in 22d ESTIMATED	READOUT A Study to Evaluate How Safe Pozelimab + Cemdisiran Combination Therapy is and H Phase 3 · Paroxysmal Nocturnal Hemoglobinuria	REGN REGENERON PHARMACEUTICALS, I	Ravulizumab, Pozelimab, Cemdisiran, Ecul	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-12 in 22d ESTIMATED	READOUT A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-98634 Phase 1/2 · Multiple Myeloma	BMY BRISTOL MYERS SQUIBB CO	CC-92480, Tazemetostat, BMS-986158, Tram	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-12 in 22d ESTIMATED	READOUT A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Particip Phase 3 · Metastatic Castrate-sensitive Prostate Cancer	Janssen Research & Development, LL	Apalutamide, Androgen-deprivation Therap	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-13 in 23d ESTIMATED	READOUT A Study of AAV9 Gene Therapy in Participants With Canavan Disease (CANaspire Cli Phase 1/2 · Canavan Disease	Aspa Therapeutics	AAV9 BBP-812	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-13 in 23d ESTIMATED	READOUT Clinical Trial to Evaluate the Safety and Efficacy of DWN12088 in Patients With Phase 2 · Idiopathic Pulmonary Fibrosis	Daewoong Pharmaceutical Co. LTD.	DWN12088	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-13 in 23d ESTIMATED	READOUT A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants Phase 1/2 · Melanoma, Hodgkin Lymphoma	GlaxoSmithKline	Cobolimab, Dostarlimab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-14 in 24d ESTIMATED	READOUT A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab ( Phase 3 · Chronic Rhinosinusitis With Nasal Polyps	SNY Sanofi	Itepekimab (SAR440340), Mometasone furoa	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-14 in 24d ESTIMATED	READOUT ENERGY 2: Evaluation of the Efficacy and Safety of INZ-701 in Infants With ENPP1 Phase 3 · Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency, Autosomal Recessive Hypophosphatemic Rickets	Inozyme Pharma	INZ-701	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-15 in 25d ESTIMATED	READOUT Microdystrophin Gene Transfer Study in Adolescents and Children With DMD Phase 1/2 · Duchenne Muscular Dystrophy	SLDB Solid Biosciences Inc.	SGT-001	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-15 in 25d ESTIMATED	READOUT Oregovomab Plus Chemotherapy in Neo-adjuvant Setting in Newly Diagnosed Patients Phase 2 · Ovarian Neoplasm Epithelial, Ovarian Cancer	CanariaBio Inc.	Oregovomab, Paclitaxel, Carboplatin	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-15 in 25d ESTIMATED	READOUT A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Phase 3 · Ischemic Stroke; Ischemic Attack, Transient	Janssen Research & Development, LL	Milvexian	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-15 in 25d ESTIMATED	READOUT EC-104 Intravitreal Implant for the Treatment of Diabetic Macular Edema Phase 1/2 · Diabetic Macular Edema	Eclipse Life Sciences, Inc.	EC-104 high dose, EC-104 low dose, Dexam	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-15 in 25d ESTIMATED	READOUT An Open-label Study of Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combin Phase 2 · Metastatic Castration Resistant Prostate Cancer (mCRPC)	NVS NOVARTIS AG	AAA617, ARPI: Abiraterone, ARPI: Enzalut	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-15 in 25d ESTIMATED	READOUT MIST (Metabolic Intervention With Semaglutide and THR-β Therapy) Trial Phase 2 · Adult Obesity, Weight Management	Eccogene	ECC4703, Semaglutide	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-16 in 26d ESTIMATED	READOUT An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Ve Phase 1/2 · Non-Hodgkins Lymphoma	Hoffmann-La Roche	Glofitamab, Atezolizumab, Obinutuzumab,	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-18 in 28d ESTIMATED	READOUT Generic Drugs (Dapagliflozin and Saxagliptin) Treat Type 2 Diabetes Patients Wit Phase 2/3 · Type 2 Diabetes	Han Xu, M.D., Ph.D., FAPCR, Medica	Farxiga® (dapagliflozin) + Onglyza® (sax	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-19 in 29d ESTIMATED	READOUT Benralizumab Airway Remodeling Study in Severe Eosinophilic Asthmatics Phase 4 · Asthma	AZN ASTRAZENECA PLC	Benralizumab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-19 in 29d ESTIMATED	READOUT A Study to Assess Effectiveness and Safety of Deucravacitinib Compared With Plac Phase 3 · Systemic Lupus Erythematosus	BMY BRISTOL MYERS SQUIBB CO	Deucravacitinib	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-19 in 29d ESTIMATED	READOUT A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Com Phase 3 · Systemic Lupus Erythematosus	BMY BRISTOL MYERS SQUIBB CO	Deucravacitinib	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-19 in 29d ESTIMATED	READOUT A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclit Phase 2 · Breast Cancer	Hoffmann-La Roche	Tobemstomig, Pembrolizumab, Nab-Paclitax	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-19 in 29d ESTIMATED	READOUT A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In Peop Phase 2 · Atopic Dermatitis	PFE PFIZER INC	PF-07275315, PF-07264660	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-19 in 29d ESTIMATED	READOUT A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participant Phase 3 · Prurigo Nodularis	INCY INCYTE CORP	Povorcitinib	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-19 in 29d ESTIMATED	READOUT A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participant Phase 3 · Prurigo Nodularis	INCY INCYTE CORP	Povorcitinib	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-20 in 30d ESTIMATED	READOUT A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Sym Phase 2/3 · Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus	BIIB BIOGEN INC.	Litifilimab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-20 in 30d ESTIMATED	READOUT First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors Phase 1/2 · Advanced Solid Tumor, Metastatic Solid Tumor	Daiichi Sankyo	DS-3939a	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-20 in 30d ESTIMATED	READOUT A Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Phase 3 · Atopic Dermatitis	LEO Pharma	Tralokinumab + TCS	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-20 in 30d ESTIMATED	READOUT A Study to Determine the Efficacy, Safety, and Durability of Faricimab in Partic Phase 4 · Neovascular Age-related Macular Degeneration (nAMD)	Hoffmann-La Roche	Faricimab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-20 in 30d ESTIMATED	READOUT A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participan Phase 3 · Schizophrenia	Otsuka Pharmaceutical Development	SEP-363856	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-22 in 1mo ESTIMATED	READOUT A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multi Phase 3 · Progressive Multiple Sclerosis (PMS)	Hoffmann-La Roche	Ocrelizumab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-22 in 1mo ESTIMATED	READOUT A Study of Belzutifan (MK-6482) in Combination With Palbociclib Versus Belzutifa Phase 1/2 · Renal Cell Carcinoma	Merck Sharp & Dohme LLC	Belzutifan, Palbociclib	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-22 in 1mo ESTIMATED	READOUT A Safety and Efficacy Study of Dazodalibep in Participants With Sjögren's Syndro Phase 3 · Sjögren's Syndrome (SS)	AMGN AMGEN INC	Dazodalibep	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-23 in 1mo ESTIMATED	READOUT A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combinati Phase 2 · Carcinoma, Non-Small-Cell Lung	AZN ASTRAZENECA PLC	Durvalumab, Tremelimumab, Pemetrexed, Pe	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-26 in 1mo ESTIMATED	READOUT A Long-term Study of Nemolizumab (CD14152) in Participants With Prurigo Nodulari Phase 3 · Prurigo Nodularis	Galderma R&D	Nemolizumab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-26 in 1mo ESTIMATED	READOUT Coronary Computed Tomography Study to Assess the Effect of Inclisiran in Additio Phase 3 · Coronary Artery Disease	NVS NOVARTIS AG	Inclisiran sodium 300 mg	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-27 in 1mo ESTIMATED	READOUT Study of Novel Immunomodulators as Monotherapy and in Combination With Anticance Phase 2 · Hepatocellular Carcinoma, Biliary Tract Cancer	AZN ASTRAZENECA PLC	Volrustomig, Bevacizumab, Lenvatinib, Ri	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-28 in 1mo ESTIMATED	READOUT A Study to Investigate the Safety and Efficacy of RO7204239 in Combination With Phase 2/3 · Spinal Muscular Atrophy (SMA)	Hoffmann-La Roche	RO7204239, Risdiplam	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-28 in 1mo ESTIMATED	READOUT A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Phase 3 · Carcinoma, Renal Cell	Merck Sharp & Dohme LLC	Belzutifan, Pembrolizumab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-28 in 1mo ESTIMATED	READOUT An Open-label Extension Study to Evaluate Long-term Efficacy and Safety of Odevi Phase 3 · Biliary Atresia	Albireo, an Ipsen Company	Odevixibat	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-28 in 1mo ESTIMATED	READOUT A Study to Test Whether BI 771716 Helps People With an Advanced Form of Age-rela Phase 2 · Macular Degeneration, Age-related, Geographic Atrophy	Boehringer Ingelheim	BI 771716, Pegcetacoplan	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-29 in 1mo ESTIMATED	READOUT Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in P Phase 3 · Primary Immune Thrombocytopenia (ITP)	NVS NOVARTIS AG	Ianalumab, Corticosteroids	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-29 in 1mo ESTIMATED	READOUT Pasireotide s.c. in Patients With Post-Bariatric Hypoglycaemia Phase 2 · Post-Bariatric Hypoglycemia	RECORDATI GROUP	Pasireotide Diaspartate	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-30 in 1mo ESTIMATED	READOUT Venglustat in Combination With Cerezyme in Adult Patients With Gaucher Disease T Phase 2 · Gaucher Disease Type 1, Gaucher Disease Type 3	Genzyme, a Sanofi Company	venglustat (GZ402671), imiglucerase	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-30 in 1mo ESTIMATED	READOUT Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumo Phase 1/2 · Solid Tumor, Adult	Nouscom SRL	GAd-209-FSP low dose, MVA-209-FSP low do	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-30 in 1mo ESTIMATED	READOUT A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrol Phase 3 · Melanoma	PFE PFIZER INC	Encorafenib, Binimetinib, Pembrolizumab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-30 in 1mo ESTIMATED	READOUT Study to Evaluate Efficacy & Safety of Afuresertib Plus Fulvestrant in Patients Phase 3 · Breast Cancer	Laekna Limited	Afuresertib, Afuresertib/placebo	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-30 in 1mo ESTIMATED	READOUT A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Thera Phase 3 · Cystic Fibrosis	Vertex Pharmaceuticals Incorporate	VX-121/TEZ/D-IVA	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-30 in 1mo ESTIMATED	READOUT Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL Phase 2 · Advanced Cancer, Metastatic Cancer	Mirati Therapeutics Inc.	Adagrasib	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-30 in 1mo ESTIMATED	READOUT A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G Phase 1/2 · Malignant Neoplasm	Tyligand Pharmaceuticals (Suzhou)	TSN1611, TSN1611, TSN1611, TSN1611	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-30 in 1mo ESTIMATED	READOUT A Single-Arm, Blinded, Fluorescent PSMA Histopathology Trial of AS1986NS Phase 1/2 · Prostate Cancer, Prostate Cancer (Adenocarcinoma)	Antelope Surgical Solutions, Inc	AS1986NS	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-30 in 1mo ESTIMATED	READOUT 18F-mFBG Imaging for Myocardial Sympathetic Innervation Phase 2 · Heart Failure, Ischemic Cardiomyopathy	Innervate Radiopharmaceuticals LLC	18F-metaFluorobenzylguanidine, Rubidium-	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-30 in 1mo ESTIMATED	READOUT 18F-mFBG Cardiac Uptake With Lewy Body Dementia Phase 2 · Parkinson Disease (PD), Lewy Body Dementia (LBD)	Innervate Radiopharmaceuticals LLC	18F-MFBG	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-31 in 1mo ESTIMATED	READOUT A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer Phase 1/2 · Carcinoma, Non-Small-Cell Lung	TAK TAKEDA PHARMACEUTICAL CO LTD	TAK-788	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-31 in 1mo ESTIMATED	READOUT Safety and Pharmacokinetics of ODM-208 in Patients With Metastatic Castration-re Phase 1/2 · Prostate Cancer Metastatic	ORN Orion Group Holdings Inc	ODM-208, Midazolam	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-31 in 1mo ESTIMATED	READOUT A Study to Compare Safety and Efficacy of High Doses of Eteplirsen in Participan Phase 3 · Muscular Dystrophy, Duchenne	SRPT Sarepta Therapeutics, Inc.	Eteplirsen	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-31 in 1mo ESTIMATED	READOUT TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Phase 3 · Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)	TAK TAKEDA PHARMACEUTICAL CO LTD	TAK-788, Pemetrexed, Cisplatin, Carbopla	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-31 in 1mo ESTIMATED	READOUT ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic So Phase 1/2 · Advanced/Metastatic Solid Tumors	ADAG Adagene Inc.	ADG126, Pembrolizumab (KEYTRUDA®)	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-31 in 1mo ESTIMATED	READOUT Phosphatase Inhibition by Intracoronary Gene Therapy in Subjects With Non-Ischem Phase 2 · Congestive Heart Failure	AskBio Inc	AB-1002	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-31 in 1mo ESTIMATED	READOUT OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advan Phase 3 · Breast Cancer, Advanced Breast Cancer	OLMA Olema Pharmaceuticals, Inc.	Palazestrant, Fulvestrant, Anastrozole,	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-31 in 1mo ESTIMATED	READOUT A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Phase 3 · Asthma	Teva Branded Pharmaceutical Produc	TEV-56248, Albuterol sulfate	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-31 in 1mo ESTIMATED	READOUT Study of JK07 in Patients With Chronic Heart Failure Phase 2 · Heart Failure With Reduced Ejection Fraction, Heart Failure With Preserved Ejection Fraction	Salubris Biotherapeutics Inc	JK07	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-31 in 1mo ESTIMATED	READOUT A Study Investigating the Efficacy and Safety of Intravitreal (IVT) Injections o Phase 3 · Geographic Atrophy	ANNX Annexon, Inc.	Vonaprument	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-31 in 1mo ESTIMATED	READOUT A Study to Evaluate the Effect of Venetoclax on Participants Receiving a Covalen Phase 2 · Chronic Lymphocytic Leukemia	Genentech, Inc.	Venetoclax, cBTKi Monotherapy	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-31 in 1mo ESTIMATED	READOUT A Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCLC Phase 2 · MTAP-deleted NSCLC	AMGN AMGEN INC	anvumetostat	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-31 in 1mo ESTIMATED	READOUT A Study to Investigate LP352 in Children and Adults With Developmental and Epile Phase 3 · Developmental and Epileptic Encephalopathy	Longboard Pharmaceuticals	LP352	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-31 in 1mo ESTIMATED	READOUT A Study of Setmelanotide in Patients With Prader-Willi Syndrome Phase 2 · Prader-Willi Syndrome, Obesity	RYTM RHYTHM PHARMACEUTICALS, INC.	Setmelanotide	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-31 in 1mo ESTIMATED	READOUT A Study of SPY072 in Rheumatic Disease Phase 2 · Rheumatoid Arthritis, Psoriatic Arthritis	SYRE Spyre Therapeutics, Inc.	SPY002-072	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-31 in 1mo ESTIMATED	READOUT A Phase 1/2 Study of the Safety and Tolerability of MT-125 in GBM Patients Phase 1/2 · Glioblastoma (GBM)	Myosin Therapeutics Inc.	MT-125	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-31 in 1mo ESTIMATED	READOUT A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Radiological Phase 3 · Relapsing Multiple Sclerosis	TG Therapeutics, Inc.	Ublituximab, Ublituximab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-31 in 1mo ESTIMATED	READOUT Study to Evaluate the Potential Effects of KH-001 on Intravaginal Ejaculatory La Phase 2 · Premature Ejaculation	Kadence Bio	KH-001 ODT	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-31 in 1mo ESTIMATED	READOUT Effect of FB301 on Vaginal Bacterial Profile in Women With Asymptomatic Vaginal Phase 2 · Vaginal Dysbiosis	Freya Biosciences ApS	FB-301, Chlorhexidine (0.5%) Vaginal Cle	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11 (month) in 1mo ESTIMATED	READOUT Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharma Phase 1/2 · Leukemia, Myeloid, Acute, Refractory AML	Aptose Biosciences Inc.	Tuspetinib, Venetoclax Oral Tablet, Azac	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11 (month) in 1mo ESTIMATED	READOUT A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Wa Phase 2 · Colorectal Cancer Stage II, Colorectal Cancer Stage III	BNTX BioNTech SE	RO7198457 intravenous (IV), Observationa	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11 (month) in 1mo ESTIMATED	READOUT Oral Pyridoxal 5'-Phosphate for the Treatment of Patients With PNPO Deficiency Phase 3 · Pyridox(am)Ine 5'-Phosphate Oxidase Deficiency	MCUJF MEDICURE INC	Pyridoxal Phosphate	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11-01 in 1mo ESTIMATED	READOUT Study of BBP-418 in Patients With LGMD2I Phase 2 · LGMD2I	ULS UL Solutions Inc.	BBP-418	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11 (month) in 1mo ESTIMATED	READOUT Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax Phase 2 · Chronic Lymphocytic Leukemia (CLL)	ABBV AbbVie Inc.	Venetoclax, Obinutuzumab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11 (month) in 1mo ESTIMATED	READOUT A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Comb Phase 1/2 · Relapsed/Refractory Multiple Myeloma	ONC BeOne Medicines Ltd.	Sonrotoclax, Dexamethasone, Carfilzomib,	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11 (month) in 1mo ESTIMATED	READOUT A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participant Phase 1/2 · B-cell Malignancy, Marginal Zone Lymphoma	ONC BeOne Medicines Ltd.	Tacabrutideg	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11 (month) in 1mo ESTIMATED	READOUT A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patien Phase 3 · Gastro-enteropancreatic Neuroendocrine Tumor	Camurus AB	CAM2029, Octreotide LAR, Lanreotide ATG	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11-01 in 1mo ESTIMATED	READOUT An Efficacy and Safety Study of Clemizole HCl in Patients With Lennox-Gastaut Sy Phase 3 · Lennox Gastaut Syndrome	Epygenix	Clemizole HCl	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11 (month) in 1mo ESTIMATED	READOUT Safety and Efficacy Study of Cenobamate in Pediatric Subjects 2-17 Years of Age Phase 3 · Partial Epilepsy	SK Life Science, Inc.	Xcopri	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11 (month) in 1mo ESTIMATED	READOUT Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 in Patients Phase 3 · Multiple Sclerosis	IMUX IMMUNIC, INC.	IMU-838 tablets	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11 (month) in 1mo ESTIMATED	READOUT Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 in Patients W Phase 3 · Multiple Sclerosis, Relapsing-Remitting	IMUX IMMUNIC, INC.	IMU-838 tablets	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11 (month) in 1mo ESTIMATED	READOUT Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients W Phase 3 · Atherosclerotic Cardiovascular Disease	NAMS NewAmsterdam Pharma Co N.V.	Obicetrapib	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11 (month) in 1mo ESTIMATED	READOUT Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Fo Phase 2 · High Grade Ovarian Cancer, Primary Peritoneal Cancer	ABBV AbbVie Inc.	Mirvetuximab soravtansine, Carboplatin	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11 (month) in 1mo ESTIMATED	READOUT Phase 1b/2 Study to Evaluate ABT-101 in Solid Tumor and NSCLC Patients Phase 1/2 · Advanced Solid Tumor, Non Small Cell Lung Cancer	Anbogen Therapeutics, Inc.	ABT-101	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11 (month) in 1mo ESTIMATED	READOUT Safety and Preliminary Anti-Tumor Activity of TYRA-300 in Advanced Urothelial Ca Phase 1/2 · Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma	TYRA Tyra Biosciences, Inc.	TYRA-300	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11 (month) in 1mo ESTIMATED	READOUT ELACESTRANT in Women and Men With CDK4/6 Inhibitor-Naive Estrogen Receptor Posit Phase 2 · Metastatic Breast Cancer	Stemline Therapeutics, Inc.	Elacestrant	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11 (month) in 1mo ESTIMATED	READOUT (Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Can Phase 2 · Breast Neoplasms, Invasive Breast Cancer	ATOS ATOSSA THERAPEUTICS, INC.	(Z)-endoxifen, goserelin	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11-01 in 1mo ESTIMATED	READOUT Long-Term Safety & Efficacy of Apitegromab in Patients With SMA Who Completed Pr Phase 3 · Spinal Muscular Atrophy, Spinal Muscular Atrophy Type 3	SRRK Scholar Rock Holding Corp	Apitegromab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11 (month) in 1mo ESTIMATED	READOUT Gene Transfer Clinical Trial for Infantile and Late Infantile Krabbe Disease Tre Phase 1/2 · Krabbe Disease	Forge Biologics, Inc	FBX-101	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11 (month) in 1mo ESTIMATED	READOUT Study to Evaluate Adverse Events, and Change in Disease Activity, When Intraveno Phase 2 · Hepatocellular Carcinoma	ABBV AbbVie Inc.	Budigalimab, Livmoniplimab, Lenvatinib,	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11 (month) in 1mo ESTIMATED	READOUT Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and B Phase 2 · Metastatic Colorectal Cancer, CRC	CRDF Cardiff Oncology, Inc.	Onvansertib, FOLFIRI, Bevacizumab, FOLFO	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11 (month) in 1mo ESTIMATED	READOUT A Study of YL202 in Selected Patients With Advanced Solid Tumors Phase 2 · NSCLC, Breast Cancer	MediLink Therapeutics (Suzhou) Co.	YL202 should be intravenously infused	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11 (month) in 1mo ESTIMATED	READOUT A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Phase 3 · Non Muscle Invasive Bladder Cancer, Urologic Cancer	CGON CG Oncology, Inc.	Cretostimogene Grenadenorepvec, n-dodecy	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11 (month) in 1mo ESTIMATED	READOUT An Open-label Extension Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis Phase 2 · Pulmonary Sarcoidosis	Xentria, Inc.	XTMAB-16	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11 (month) in 1mo ESTIMATED	READOUT A Phase 2 Study Evaluating Safety and Tolerability of RCT2100 (CFTR mRNA) in Hea Phase 2 · Cystic Fibrosis	ReCode Therapeutics	RCT2100, RCT2100, RCT2100, Ivacaftor	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11 (month) in 1mo ESTIMATED	READOUT A Study to Evaluate Safety and Efficacy of Empasiprubart in Adults With Dermatom Phase 2 · Dermatomyositis, Myositis	ARGX ARGENX SE	Empasiprubart IV	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11 (month) in 1mo ESTIMATED	READOUT A Study to Assess the Efficacy, Safety, and Pharmacokinetics of FNP-223 to Slow Phase 2 · Progressive Supranuclear Palsy	Ferrer Internacional S.A.	FNP-223	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11 (month) in 1mo ESTIMATED	READOUT A Study Evaluating APG777 in Atopic Dermatitis Phase 2 · Atopic Dermatitis	Apogee Therapeutics, Inc.	APG777	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11 (month) in 1mo ESTIMATED	READOUT Impact of Obicetrapib and Obicetrapib Plus Repatha on Lp(a) Levels Phase 2 · Dyslipidemias	NAMS NewAmsterdam Pharma Co N.V.	obicetrapib 10 mg + obicetrapib/evolocum	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11 (month) in 1mo ESTIMATED	READOUT Leniolisib for Immune Dysregulation in PIDs Phase 2 · Primary Immunodeficiency Disorders (PIDs)	Pharming Technologies B.V.	Leniolisib	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11-01 in 1mo ESTIMATED	READOUT First-in-human Study of CRB-601-01 to Treat Patients With Advanced Solid Tumor. Phase 1/2 · Solid Tumor	CRBP Corbus Pharmaceuticals Holdi	CRB-601 monoclonal antibody, Anti-PD-1 m	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11 (month) in 1mo ESTIMATED	READOUT A Study to Investigate Sonrotoclax Combined With Zanubrutinib Versus Zanubrutini Phase 2 · Chronic Lymphocytic Leukemia	ONC BeOne Medicines Ltd.	Sonrotoclax, Zanubrutinib	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11 (month) in 1mo ESTIMATED	READOUT A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Phase 3 · Obesity	LLY ELI LILLY & Co	Retatrutide, Tirzepatide	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11 (month) in 1mo ESTIMATED	READOUT A Phase 2 Study of CAL101 in Patients With Idiopathic Pulmonary Fibrosis Phase 2 · Idiopathic Pulmonary Fibrosis	Calluna Pharma AS	CAL101	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11-01 in 1mo ESTIMATED	READOUT Tirbanibulin for Pediatric Warts Phase 4 · Warts Hand	The Skin Center Dermatology Group	Tirbanibulin ointment 1%	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11 (month) in 1mo ESTIMATED	READOUT A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With I Phase 2 · Idiopathic Hypersomnia	ALKS Alkermes plc.	ALKS 2680	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11 (month) in 1mo ESTIMATED	READOUT Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 Phase 2 · Generalized Anxiety Disorder (GAD)	ABBV AbbVie Inc.	ABBV-932, Antidepressant Therapy (ADT)	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11 (month) in 1mo ESTIMATED	READOUT Comparative PK, PD, Efficacy, and Safety Assessment of the Proposed Ocrelizumab Phase 3 · Relapsing Multiple Sclerosis	Sandoz	CYB704, Ocrevus-EU, Ocrevus-US	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11 (month) in 1mo ESTIMATED	READOUT A Study to Assess Safety and Tolerability of PCRX-201 in Subjects With Painful O Phase 2 · Osteoarthritis (OA) of the Knee	PCRX Pacira BioSciences, Inc.	Enekinragene Inzadenovec (PCRX-201)	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11 (month) in 1mo ESTIMATED	READOUT A Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 D Phase 3 · Type 1 Diabetes, Obesity	LLY ELI LILLY & Co	Tirzepatide	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11-01 in 1mo ESTIMATED	READOUT A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Phase 3 · Bipolar-I Disorder With Mania or Mania With Mixed Features	BMY BRISTOL MYERS SQUIBB CO	KarXT	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11 (month) in 1mo ESTIMATED	READOUT A Long-Term Study of Tirzepatide (LY3298176) in Adults With Type 1 Diabetes and Phase 3 · Type 1 Diabetes, Obesity	LLY ELI LILLY & Co	Tirzepatide	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11 (month) in 1mo ESTIMATED	READOUT Tibulizumab Skin Healing and Inflammation Evaluation for Lasting Defense Phase 2 · Hidradenitis Suppurativa (HS)	ZURA Zura Bio Ltd	Tibulizumab Dose A, Tibulizumab Dose B	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11 (month) in 1mo ESTIMATED	READOUT RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medic Phase 2 · Adjustment Disorder	Reunion Neuroscience Inc	RE104 for Injection	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11 (month) in 1mo ESTIMATED	READOUT Safety Study of Viaskin® Peanut Patch in Peanut-Allergic Children 1 Through 3 Ye Phase 3 · Allergy, Peanut Allergy	DBVT DBV Technologies S.A.	DBV712 250 mcg	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11 (month) in 1mo ESTIMATED	READOUT Evaluation of Efficacy and Safety of AR882 and XOI Co-administration in Uricase Phase 2 · Gout, Gouty Arthritis	Arthrosi Therapeutics	AR882 75 mg, XOI Low Dose, XOI High Dose	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11 (month) in 1mo ESTIMATED	READOUT A Study to Evaluate Tobevibart+Elebsiran Versus Bulevirtide in Chronic HDV Infec Phase 2 · Viral Hepatitis	VIR Vir Biotechnology, Inc.	Tobevibart, Elebsiran, Bulevirtide	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11 (month) in 1mo ESTIMATED	READOUT A Study of LY3938577 in Participants With Type 2 Diabetes Previously Treated Wit Phase 2 · Diabetes Mellitus, Type 2	LLY ELI LILLY & Co	LY3938577, Degludec	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11 (month) in 1mo ESTIMATED	READOUT A Study of LY4515100 in Participants With Pain Following Third Molar Removal Phase 2 · Acute Pain, Molar	LLY ELI LILLY & Co	LY4515100	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11 (month) in 1mo ESTIMATED	READOUT To Assess the Efficacy of Two Brushing Regimens: in the Reduction of Established Phase 3 · Plaque, Dental, Gingivitis	CL COLGATE PALMOLIVE CO	Colgate SNaP Total 10/10, 1.5 Taurate, C	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11-02 in 1mo ESTIMATED	READOUT A Study of Dostarlimab in Untreated dMMR/MSI-H Locally Advanced Rectal Cancer Phase 2 · Neoplasms, Rectal	GlaxoSmithKline	Dostarlimab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11-02 in 1mo ESTIMATED	READOUT A Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adult Phase 3 · Cutaneous Lupus Erythematosus	AZN ASTRAZENECA PLC	Anifrolumab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11-02 in 1mo ESTIMATED	READOUT A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti- Phase 2 · Melanoma	REGN REGENERON PHARMACEUTICALS, I	cemiplimab, Fixed Dose Combination (FDC)	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11-02 in 1mo ESTIMATED	READOUT A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Phase 3 · Bipolar Disorder Type I With Mania or Mania With Mixed Features	BMY BRISTOL MYERS SQUIBB CO	KarXT	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11-03 in 1mo ESTIMATED	READOUT 24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, Phase 3 · Chronic Spontaneous Urticaria	NVS NOVARTIS AG	LOU064 (blinded)	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11-05 in 2mo ESTIMATED	READOUT Long-term Safety and Efficacy Study of Fitusiran in Patients With Hemophilia A o Phase 3 · Hemophilia	Genzyme, a Sanofi Company	Fitusiran	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11-05 in 2mo ESTIMATED	READOUT Pediatric Long-Term Follow-up and Rollover Study Phase 4 · Diffuse Astrocytoma, Anaplastic Astrocytoma	NVS NOVARTIS AG	dabrafenib, trametinib	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11-05 in 2mo ESTIMATED	READOUT Rollover Study to Provide Continued Treatment for Participants With B-Cell Malig Phase 2 · B-Cell Malignancies	INCY INCYTE CORP	Parsaclisib, parsaclisib + itacitinib, p	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11-06 in 2mo ESTIMATED	READOUT Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Phase 2 · Hodgkin Lymphoma	Merck Sharp & Dohme LLC	pembrolizumab, doxorubicin, vinblastine,	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11-06 in 2mo ESTIMATED	READOUT A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab ( Phase 3 · Chronic Rhinosinusitis With Nasal Polyps	SNY Sanofi	Itepekimab (SAR440340), Mometasone furoa	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11-09 in 2mo ESTIMATED	READOUT A Platform Study of Novel Immunotherapy Combinations in Participants With Previo Phase 2 · Lung Cancer, Non-Small Cell	GlaxoSmithKline	Pembrolizumab, Dostarlimab, Belrestotug,	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11-11 in 2mo ESTIMATED	READOUT Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuz Phase 3 · Breast Cancer; HER2-positive; Metastatic	AZN ASTRAZENECA PLC	Trastuzumab deruxtecan, Taxane, Pertuzum	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11-11 in 2mo ESTIMATED	READOUT PRGN-2009 in Combination With Pembrolizumab in Patients With Recurrent or Metast Phase 2 · Cervical Cancer, HPV-Related Carcinoma	PGEN PRECIGEN, INC.	PRGN-2009 plus Pembrolizumab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11-13 in 2mo ESTIMATED	READOUT A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination Wi Phase 1/2 · Advanced Solid Tumors	REGN REGENERON PHARMACEUTICALS, I	REGN7075, Cemiplimab, Platinum-based dou	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11-13 in 2mo ESTIMATED	READOUT A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compar Phase 3 · Breast Cancer	Hoffmann-La Roche	Inavolisib, Fulvestrant, Alpelisib, Bupr	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11-13 in 2mo ESTIMATED	READOUT Study of Olatorepatide in Adult Participants Living With Overweight or Obesity i Phase 2 · Overweight or Obesity	REGN REGENERON PHARMACEUTICALS, I	Olatorepatide	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11-15 in 2mo ESTIMATED	READOUT Efficacy of M640 in Acute Lumbosacral Musculoskeletal Conditions. Phase 4 · Sciatica Acute, Lumbar Spinal Stenosis	Primus Pharmaceuticals	Metaxalone 640 mg Oral Tablet	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11-15 in 2mo ESTIMATED	READOUT Evaluate Efficacy and Safety of PA5108 Ocular Implants in Primary Open Angle Gla Phase 2 · Glaucoma, Open-Angle, Ocular Hypertension	PolyActiva Pty Ltd	PA5108 Ocular Implant low dose, PA5108 O	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11-16 in 2mo ESTIMATED	READOUT A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Gener Phase 2/3 · Generalized Myasthenia Gravis	UCB Biopharma SRL	Zilucoplan	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11-17 in 2mo ESTIMATED	READOUT AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2 Phase 2 · Gastric Cancer, Gastroesophageal Junction Cancer	AZN ASTRAZENECA PLC	AZD0901, 5-Fluorouracil, Leucovorin, l-l	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11-17 in 2mo ESTIMATED	READOUT A Study to Investigate the Course of Synovial Hypertrophy in Patients With Haemo Phase 4 · Haemophilia A (Moderate or Severe), Hemophilia, Classic	Swedish Orphan Biovitrum	Efanesoctocog alfa	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11-18 in 2mo ESTIMATED	READOUT Pharmacogenomics ANDA SNP Clinical Study - Etoposide and Single Nucleotide Polym Phase 2/3 · Small Cell Lung Cancer	Han Xu, M.D., Ph.D., FAPCR, Medica	ETOPOSIDE - Usual, ETOPOSIDE - Study	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11-18 in 2mo ESTIMATED	READOUT Pharmacogenomics IND Commercial SNP Clinical Study - Abiraterone and Single Nucl Phase 2/3 · Prostate Cancer	Han Xu, M.D., Ph.D., FAPCR, Sponso	Abiraterone - Usual, Abiraterone - Study	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11-18 in 2mo ESTIMATED	READOUT A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Ac Phase 3 · Sjögren's Syndrome	BMY BRISTOL MYERS SQUIBB CO	Deucravacitinib	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11-18 in 2mo ESTIMATED	READOUT Pharmacogenomics IND SNP Clinical Trial - Alectinib and Single Nucleotide Polymo Phase 2/3 · ALK-Positive Non-Small Cell Lung Cancer (NSCLC)	Han Xu, M.D., Ph.D., FAPCR, Medica	ALECENSA - alectinib hydrochloride capsu	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change